Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) received a notice from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to approve the company's Class 1 innovative drug for injectable remazolam toluene sulfonate as a new indication for sedation during mechanical ventilation during intensive care.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.